tbuckley/cabot-search huggingface dataset:
Intensive Care Society has set up a centre for national audit
Authors: K. Rowan
Journal: BMJ (1996)

EDITOR,—The issues raised by David H Sochart and colleagues in their editorial on the need for a national arthroplasty register are similar to those that the Intensive Care Society faced in 1990.1 Although many intensive care units were collecting data on their patients, the way in which the data were collected was not standardised, which made valid aggregation of data impossible.

The society, building on its study of outcomes at 26 units,2 sought funds to establish a national, comparative audit …
Original Articles : CT Detection of Hepatocellular Carcinoma in Advanced Liver Cirrhosis : Correlation of Helical CT and Explanted Liver
Authors: Jae Hoon Lim, Min Ju Kim, Liu Wei Chiang, Hyo Keun Lim, Cheol Keun Park, Seung Woon Paik, Jae Won Joh, Kwang Cheol Koh
Journal: Clinical and Molecular Hepatology (2002)

Objective: The objective of this study was evaluate the diagnostic efficacy of three-phase helical dynamic CT in the detection of hepatocellular carcinomas in patients with advanced liver cirrhosis. Materials and Methods: Three-phase helical dynamic CT in 77 patients with advanced liver cirrhosis was evaluated prospectively before orthotopic liver transplantation. The histopathologically confirmed hepatocellular carcinomas in the explanted livers were compared with pretransplantation CT results by one-to-one correlation. Results: Histopathologic examination of the explanted livers revealed 72 hepatocellular carcinomas in 41 patients. The size of the hepatocellular carcinomas was 0.5-14.0 cm (mean, 1.6 cm). The use of helical dynamic CT enabled the detection of 38 of 72 hepatocellular carcinomas (sensitivity, 53%). Fifteen of 35 (43%) hepatocellular carcinomas smaller than 2 cm and 23 of 37 (62%), hepatocellular carcinomas ranging from 2.0 cm to 14.0 cm were detected. Patient sensitivity and specificity in the detection of hepatocellular carcinoma were 81% (33/41) and 94% (34/36), respectively. Conclusions: Three-phase helical dynamic CT is insensitive for detection of hepatocellular carcinomas in patients with advanced liver cirrhosis, especially for hepatocellular carcinomas smaller than 2 cm.(Korean J Hepatol 2002;8:201-208)
Decreased Correlation Between the Agarose Leukocyte Migration Inhibition Assay and Delayed Cutaneous Hypersensitivity Response to Purified Protein Derivative in Cancer Patients2
Authors: Darwin O. Chee, E. Carmack Holmes, Donald L. Morton
Journal: JNCI Journal of the National Cancer Institute (1978)

Journal Article Decreased Correlation Between the Agarose Leukocyte Migration Inhibition Assay and Delayed Cutaneous Hypersensitivity Response to Purified Protein Derivative in Cancer Patients Get access Darwin O. Chee, Darwin O. Chee 3Department of Surgical Services, Veterans Administration Hospital, Sepulveda, Calif. 913434Division of Oncology, Department of Surgery, University of California, School of Medicine, Los Angeles, Calif. 90024 Search for other works by this author on: Oxford Academic PubMed Google Scholar E. Carmack Holmes, E. Carmack Holmes 3Department of Surgical Services, Veterans Administration Hospital, Sepulveda, Calif. 913434Division of Oncology, Department of Surgery, University of California, School of Medicine, Los Angeles, Calif. 90024 Search for other works by this author on: Oxford Academic PubMed Google Scholar Donald L. Morton Donald L. Morton 3Department of Surgical Services, Veterans Administration Hospital, Sepulveda, Calif. 913434Division of Oncology, Department of Surgery, University of California, School of Medicine, Los Angeles, Calif. 90024 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 60, Issue 4, April 1978, Pages 769–772, https://doi.org/10.1093/jnci/60.4.769 Published: 01 April 1978 Article history Received: 11 August 1977 Accepted: 17 October 1977 Published: 01 April 1978
Abstract 15469: Procedural Sedation With Dexmedetomidine During Ablation of Atrial Fibrillation: A Randomized Controlled Trial
Authors: Akinori Sairaku, Yukihiko Yoshida, Monami Ando, Haruo Hirayama, Yukiko Nakano, Yasuki Kihara
Journal: Circulation (2013)

Introduction: Procedural sedation by non-anesthesiologists with GABAergic anesthetics has the potential risk of fatal respiratory depression. Dexmedetomidine works its sedative action via α2-adrene...
A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance
Authors: Cholsoon Jang, Sungwhan F Oh, Shogo Wada, Glenn C Rowe, Laura Liu, Mun Chun Chan, James Rhee, Atsushi Hoshino, Boa Kim, Ayon Ibrahim, Luisa G Baca, Esl Kim, Chandra C Ghosh, Samir M Parikh, Aihua Jiang, Qingwei Chu, Daniel E Forman, Stewart H Lecker, Saikumari Krishnaiah, Joshua D Rabinowitz, Aalim M Weljie, Joseph A Baur, Dennis L Kasper, Zoltan Arany
Journal: Nature Medicine (2016)
Phase II clinical trial of pasireotide LAR in patients with metastatic neuroendocrine tumors.
Authors: Jonathan R. Strosberg, Helen Jump, Tiffany Valone, Jill Weber, Vilay H. Khandelwal, Pamela L. Kunz
Journal: Journal of Clinical Oncology (2014)

241 Background: Pasireotide LAR is a novel somatostatin analog (SSA) with avid binding to somatostatin receptor subtypes (SSTR) 1, 2, 3 and 5. It has been studied in patients who are refractory to SSAs, but has not yet been investigated in treatment naïve patients. Methods: We performed a phase II trial of first-line pasireotide LAR 60mg q4 weeks in patients with metastatic low and intermediate grade NETs. Prior systemic therapy, including octreotide and lanreotide, was not permitted. The primary endpoint was PFS. Immunohistochemical SSTR subtype analysis was performed on archival tissue. Results: 29 patients were enrolled of whom 28 patients were assessable for response. Primary sites included small intestine (14 pts), pancreas (6), rectal (2), unknown (4) and other sites (3). 13 patients had low-grade and 16 patients had intermediate-grade tumors. Best radiographic response was stable disease in 17 patients (60%), progressive disease in 10 patients (36%) and partial response in 1 patient (4%). Median PFS was 12.2 months (95% CI 7.7-17.5). The 1 year OS rate was 92% (CI 72%-98%). Although generally well tolerated, pasireotide LAR treatment was associated with a 79% rate of hyperglycemia. 4 patients (14%) developed grade 3 hyperglycemia. 6 patients were started on insulin during the trial period, and at least 2 have remained on long-term insulin therapy despite discontinuation of pasireotide. Conclusions: Although the median PFS of 12.2 months in a heterogeneous population of NET patients is encouraging, the high rate of hyperglycemia requiring intervention represents a significant concern. Future studies of pasireotide should explore specific populations such as octreotide refractory patients. Clinical trial information: NCT01253161.
Integrated Whole Genome and Transcriptome Analysis Identified a Therapeutic Minor Histocompatibility Antigen in a Splice Variant of <i>ITGB2</i>
Authors: Margot J. Pont, Dyantha I. van der Lee, Edith D. van der Meijden, Cornelis A.M. van Bergen, Michel G.D. Kester, Maria W. Honders, Martijn Vermaat, Matthias Eefting, Erik W.A. Marijt, Szymon M. Kielbasa, Peter A.C. 't Hoen, J.H. Frederik Falkenburg, Marieke Griffioen
Journal: Clinical Cancer Research (2016)

In HLA-matched allogeneic hematopoietic stem cell transplantation (alloSCT), donor T cells recognizing minor histocompatibility antigens (MiHAs) can mediate desired antitumor immunity as well as undesired side effects. MiHAs with hematopoiesis-restricted expression are relevant targets to augment antitumor immunity after alloSCT without side effects. To identify therapeutic MiHAs, we analyzed the in vivo immune response in a patient with strong antitumor immunity after alloSCT.T-cell clones recognizing patient, but not donor, hematopoietic cells were selected for MiHA discovery by whole genome association scanning. RNA-sequence data from the GEUVADIS project were analyzed to investigate alternative transcripts, and expression patterns were determined by microarray analysis and qPCR. T-cell reactivity was measured by cytokine release and cytotoxicity.T-cell clones were isolated for two HLA-B*15:01-restricted MiHA. LB-GLE1-1V is encoded by a nonsynonymous SNP in exon 6 of GLE1 For the other MiHAs, an associating SNP in intron 3 of ITGB2 was found, but no SNP disparity was present in the normal gene transcript between patient and donor. RNA-sequence analysis identified an alternative ITGB2 transcript containing part of intron 3. qPCR demonstrated that this transcript is restricted to hematopoietic cells and SNP-positive individuals. In silico translation revealed LB-ITGB2-1 as HLA-B*15:01-binding peptide, which was validated as hematopoietic MiHA by T-cell experiments.Whole genome and transcriptome analysis identified LB-ITGB2-1 as MiHAs encoded by an alternative transcript. Our data support the therapeutic relevance of LB-ITGB2-1 and illustrate the value of RNA-sequence analysis for discovery of immune targets encoded by alternative transcripts. Clin Cancer Res; 22(16); 4185-96. ©2016 AACR.
Sticky Palms Following Use of Proton-Pump Inhibitors
Authors: Salim Alkeraye, Yves Baclet, Emmanuel Delaporte
Journal: JAMA Dermatology (2016)

5 reported that patients are willing to trade decreased safety (adverse effects) for increased effectiveness (better therapeutic outcome) or increased convenience (compatibility with personal and professional life).In contrast, Seston et al 6 reported that patients are willing to trade decreased effectiveness (time to achieve moderate skin improvement) to increase safety (minimize the risk).Our focus group study confirmed that the trade-offs in treatment decisions are highly personalized based on the interpretation and relative value placed on effectiveness, safety, and convenience.To facilitate patient decision-making that incorporates personalized values related to treatment trade-offs, a PDA for patients with psoriasis must elicit individual perceptions of the trade targets.If the PDA offers ranked lists of treatments according to effectiveness, safety, or convenience, the PDA should first investigate patients' own conceptions of these 3 factors.This approach may help clinicians effectively and cooperatively address patients' risk-benefit concerns and to incorporate patient preferences within the consultation.
A phase II trial of interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma.
Authors: D H Ilson, R J Motzer, R L Kradin, N J Vogelzang, D F Bajorin, H I Scher, D Nanus, P O'Moore, K Marathias, G J Bosl
Journal: Journal of Clinical Oncology (1992)

PURPOSE A phase II trial that used a regimen of interleukin-2 (IL-2) and interferon alfa-2a (IFN-alpha) was undertaken to evaluate the efficacy of this combination in the treatment of metastatic renal cell carcinoma. PATIENTS AND METHODS Thirty-four assessable patients were treated with one to two induction cycles of IL-2 administered by continuous intravenous (IV) infusion at a dose of 3 x 10(6) U/m2/d [corrected] for 4 days per week plus IFN-alpha administered by subcutaneous injection at a dose of 5 x 10(6) U/m2/d [corrected] for 4 days per week for 3 consecutive weeks. A maintenance regimen of IL-2 2 x 10(6) U/m2/d [corrected] given by continuous IV infusion for 5 days per week plus IFN-alpha subcutaneously at a dose of 6 x 10(6) U/m2/d [corrected] that was given 3 days per week for 3 weeks was administered for one to five cycles. Twenty-eight patients (82%) completed one to two induction cycles, and 14 patients (41%) received maintenance doses. RESULTS Major responses were achieved in four patients (12%), which included one complete response (CR) in a bone metastasis. Responses were observed in patients both with and without prior nephrectomy as well as in a primary tumor. Toxicity was moderately severe and included two treatment-related deaths. CONCLUSIONS In view of the minimal antitumor activity and associated toxicity, the combination of IL-2 and IFN-alpha in this trial cannot be recommended. The investigation of new cytokines and the identification of biologic prognostic factors for a response to immunologic therapy are essential.
Tumor Induction by Plastic Films: Attempt to Correlate Carcinogenic Activity With Certain Physicochemical Properties of the Implant&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: R L Carter, F J Roe, R Peto
Journal: JNCI Journal of the National Cancer Institute (1971)

Journal Article Tumor Induction by Plastic Films: Attempt to Correlate Carcinogenic Activity With Certain Physicochemical Properties of the Implant Get access R. L. Carter, R. L. Carter Chester Beatty Research Institute, Institute of Cancer Research, Royal Cancer Hospital, London, S.W.3., England; and The Department of the Regius Professor of Medicine, The Radcliffe Infirmary, Oxford, England Search for other works by this author on: Oxford Academic PubMed Google Scholar F. J. C. Roe, F. J. C. Roe Chester Beatty Research Institute, Institute of Cancer Research, Royal Cancer Hospital, London, S.W.3., England; and The Department of the Regius Professor of Medicine, The Radcliffe Infirmary, Oxford, England Search for other works by this author on: Oxford Academic PubMed Google Scholar Richard Peto Richard Peto Chester Beatty Research Institute, Institute of Cancer Research, Royal Cancer Hospital, London, S.W.3., England; and The Department of the Regius Professor of Medicine, The Radcliffe Infirmary, Oxford, England Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 46, Issue 6, June 1971, Pages 1277–1289, https://doi.org/10.1093/jnci/46.6.1277 Published: 01 June 1971 Article history Received: 09 December 1970 Accepted: 26 February 1971 Published: 01 June 1971
A Phase 1B Study of the Anti-Cancer Stem Cell Agent Demcizumab (Dem), Pemetrexed (Pem) &amp; Carboplatin (Carbo) in Pts with 1St Line Non-Squamous Nsclc
Authors: R. Stagg, M. McKeage, D. Kotasek, B. Markman, M. Hidalgo, M. Millward, M. Jameson, D. Harris, J. Dupont, B. Hughes
Journal: Annals of Oncology (2014)
Free Paper Session : LC & Liver Fibrosis ; Bioimaging by Quantum-dot and anti-fibrotic therapy using RNA interference against TGFβ in Liver cirrhosis mouse model (초)
Authors: Sung Woo Hong, Won Hee Hur, Jung Eun Choi, Kwang Soo Lyoo, Sei Kwang Hahn, Seung Kew Yoon
Journal: Clinical and Molecular Hepatology (2011)
Insomnia, Quality Of Life and MPN Symptom Burden: An Analysis By The MPN Quality Of Life International Study Group (MPN-QOL ISG)
Authors: Holly Lynn Geyer, Amylou Constance Dueck, Robyn M. Emanuel, Keith Cannon, Jean-Jacques Kiladjian, Stephanie Slot, Sonja Zweegman, Peter Boekhorst, Suzan Commandeur, Harry C. Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Dohner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Françoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N Harrison, Deepti H Radia, Pablo J. Muxi, Norman I Maldonado, Carlos Besses, Francisco Cervantes, Peter Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Francesco Passamonti, Bjorn Andreasson, Maria Ferrari, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Peihong Zhang, Robert Peter Peter Gale, Ruben A. Mesa
Journal: Blood (2013)
Macrophages and HIV-1: An Unhealthy Constellation
Authors: Quentin J. Sattentau, Mario Stevenson
Journal: Cell Host & Microbe (2016)

Lentiviruses have a long-documented association with macrophages. Abundant evidence exists for in vitro and, in a tissue-specific manner, in vivo infection of macrophages by the primate lentiviruses HIV-1 and SIV. However, macrophage contribution to aspects of HIV-1 and SIV pathogenesis, and their role in viral persistence in individuals on suppressive antiretroviral therapy, remains unclear. Here we discuss recent evidence implicating macrophages in HIV-1-mediated disease and highlight directions for further investigation.
A Phase I Study Of The Histone Deacetylase Inhibitor Entinostat Plus Clofarabine For Philadelphia Chromosome Negative, Poor Risk (Newly Diagnosed Older Adults or Adults with Relapsed and Refractory Disease) Acute Lymphoblastic Leukemia Or Bilineage/Biphenotypic Leukemia
Authors: Hetty E Carraway, Judith E. Karp, Ivana Gojo, Keith W. Pratz, Nilanjan Ghosh, Steven D. Gore, Margaret M. Showel, Mark Levis, B. Douglas Smith, Jacqueline Greer, James G. Herman, Lia Gore, Min-Jung Lee, Sunmin Lee, Peter Ordentlich, Richard Piekarz, Jane Trepel
Journal: Blood (2013)
Health Care, Family, and Community Factors Associated with Mental, Behavioral, and Developmental Disorders in Early Childhood — United States, 2011–2012
Authors: Rebecca H. Bitsko, Joseph R. Holbrook, Lara R. Robinson, Jennifer W. Kaminski, Reem Ghandour, Camille Smith, Georgina Peacock
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Sociodemographic, health care, family, and community attributes have been associated with increased risk for mental, behavioral, and developmental disorders (MBDDs) in children (1,2). For example, poverty has been shown to have adverse effects on cognitive, socio-emotional, and physical development (1). A safe place to play is needed for gross motor development, and accessible health care is needed for preventive and illness health care (3). Positive parenting and quality preschool interventions have been shown to be associated with prosocial skills, better educational outcomes, and fewer health risk behaviors over time (2). Protective factors for MBDDs are often shared (4) and conditions often co-occur; therefore, CDC considered MBDDs together to facilitate the identification of factors that could inform collaborative, multidisciplinary prevention strategies. To identify specific factors associated with MBDDs among U.S. children aged 2-8 years, parent-reported data from the most recent (2011-2012) National Survey of Children's Health (NSCH) were analyzed. Factors associated with having any MBDD included inadequate insurance, lacking a medical home, fair or poor parental mental health, difficulties getting by on the family's income, employment difficulties because of child care issues, living in a neighborhood lacking support, living in a neighborhood lacking amenities (e.g., sidewalks, park, recreation center, and library), and living in a neighborhood in poor condition. In a multivariate analysis, fair or poor parental mental health and lacking a medical home were significantly associated with having an MBDD. There was significant variation in the prevalence of these and the other factors by state, suggesting that programs and policies might use collaborative efforts to focus on specific factors. Addressing identified factors might prevent the onset of MBDDs and improve outcomes among children who have one or more of these disorders.
Low-Concentration PM <sub>2.5</sub> and Mortality: Estimating Acute and Chronic Effects in a Population-Based Study
Authors: Liuhua Shi, Antonella Zanobetti, Itai Kloog, Brent A. Coull, Petros Koutrakis, Steven J. Melly, Joel D. Schwartz
Journal: Environmental Health Perspectives (2015)

Both short- and long-term exposures to fine particulate matter (≤ 2.5 μm; PM2.5) are associated with mortality. However, whether the associations exist at levels below the new U.S. Environmental Protection Agency (EPA) standards (12 μg/m3 of annual average PM2.5, 35 μg/m3 daily) is unclear. In addition, it is not clear whether results from previous time series studies (fit in larger cities) and cohort studies (fit in convenience samples) are generalizable.
Multiplicity of Cell Response to the BAI Strain A (Myeloblastosis) Avian Tumor Virus. I. Nephroblastoma (Wilms' Tumor): Gross and Microscopic Pathology&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;
Authors: Hideo Ishiguro, Dorothy Beard, J. R. Sommer, Ursula Heine, Guy de Thé, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1962)

The gross and microscopic features of the renal tumor occurring in chickens exposed to the BAI strain A (myeloblastosis) avian tumor virus are described. The neoplasm is a growth of mixed tissue components consisting of epithelial structures of variable resemblance to normal nephronic elements enclosed in a stroma of differing states of differentiation between primitive epithelium and mesenchyme to frank, disseminated, or circumscribed sarcoma. In addition, deposits of cartilage and osteoid, as well as loci of epithelial keratinization are frequently observed. In all aspects of histologic composition, this virus-induced tumor closely resembles the nephroblastoma occurring under natural conditions in man (Wilms' tumor), rabbits, swine, and chickens. The findings support the concept that the growth originates in nephrogenic elements residual in the postembryonic kidney and suggest a possible mechanism for maintenance of continuous growth.
Cell-Associated Virions and Nucleoids of a Murine Leukemia Virus2
Authors: S. Panem, W. H. Kirsten
Journal: JNCI Journal of the National Cancer Institute (1973)

Cell-associated nucleoids and virions were identified in the cytoplasm of established mouse cell lines infected with a murine leukemia virus. The buoyant density of the cell-associated virions ranged from 1.14–1.16 g/cm3,- buoyant densities of cell-associated nucleoids were 1.22–1.24 g/cm3 after cen-trifugation through potassium citrate gradients. Cell-associated virions and nucleoids were isolated from potassium citrate gradient fractions that did not contain ribosomal RNAs. The cell-associated virions and nucleoids were distinguished from polysomes and mitochondria by their resistance to disruption by ethylene-diaminetetraacetic acid (EDTA) and RNAse. Cell-associated virions and nucleoids incorporated3H-uridine within 10 minutes of exposure to label. Actinomycin D inhibited de novo incorporation of3H-uridine into these structures within 20 minutes, but did not inhibit the maturation of previously labeled cell-associated virions and nucleoids into extracellular virions. Cell-associated virions contained 2 RNA species with sedimentation coefficients of 36 S and 20–24 S.
Comparative Effectiveness of Mepolizumab and Omalizumab in Severe Asthma: An Indirect Comparison
Authors: Gillian Stynes, Sarah Cockle, Necdet Gunsoy, Daniel C. Park, Jaro Wex, Jenny Wilson, Eric Bradford, Frank C. Albers, Rafael Alfonso-Cristancho
Journal: Journal of Allergy and Clinical Immunology (2016)